​" Understanding the Development History of PD-1/PD-L1 Treatment in China " , released in 2021, is liked by many readers.

 

 

first-line indications

First-line indications First-line indications

 

The first-line indications involve 9 cancers, namely:

The first-line indications involve 9 cancers, which are: The first-line indications involve 9 cancers, which are:

 

 

1.

1.

 

• PD-1 4 models ( K drug, tislelizumab, camrelizumab, sintilimab )

• PD-L1 1 ( sugalimumab )

• Although the T drug is only approved for non-squamous first-line NSCLC , it only owns the indications for adjuvant treatment of NSCLC, while the I drug only owns the consolidation treatment of NSCLC.

  
  

PD-1 4 models ( K drug, tislelizumab, camrelizumab, sintilimab )

PD-1 4 models ( K drug, tislelizumab, camrelizumab, sintilimab )

PD-1 4 models ( K drug, tislelizumab, camrelizumab, sintilizumab K drug, tislelizumab, camrelizumab, sintilimab )

PD-L1 1 ( sugalimumab )

PD-L1 1 ( sugalimumab )

PD-L1 type 1 ( sugelimumab )

Although the T drug is only approved for non-squamous first-line NSCLC , it only owns the indications for adjuvant treatment of NSCLC, while the I drug only owns the consolidation treatment of NSCLC.

Although the T drug is only approved for non-squamous first-line NSCLC , it only owns the indications for adjuvant treatment of NSCLC, while the I drug only owns the consolidation treatment of NSCLC.

Although T drug T drug is only approved for non-squamous first-line NSCLC , it only owns the indications for adjuvant treatment of NSCLC, while I drug only owns NSCLC consolidation therapy.

2.

2.

 

3.

3.

 

4.

4.

 

5.

5.

 

6.

6.
Squamous cell carcinoma of the head and neck 6.
Squamous cell carcinoma of the head and neck : a total of 1 ( K medicine and K medicine ), it seems that the domestic PDX has no layout
.

 

 

7.
Colorectal cancer : There is a total of 1 type ( K drug ), in fact, with the help of MSI-H, I hope that Biomarker will be removed in the future to break through colorectal cancer in a down-to-earth manner
.

7.
colorectal cancer 7.
colorectal cancerColorectal cancer : There is a total of 1 ( K drug K drug ), in fact, with the help of MSI-H, I hope that Biomarker will be removed in the future, and colorectal cancer will be broken down in a down-to-earth manner
.

 

 

8.
Nasopharyngeal cancer : a total of 2 models ( toripalizumab, camrelizumab ), Guangdong cancer, Chinese cancer treatment, only domestic PD-1 is listed, and BeiGene’s Phase III data is also tight Followed
.

8.
Nasopharyngeal carcinoma 8.
Nasopharyngeal carcinoma : a total of 2 types ( Toripalizumab, Camrelizumab, Toripalizumab , Camrelizumab ), Guangdong Cancer, China Cancer Treatment in China , only the domestic PD-1 is listed, followed by the third-phase data of Baekje
.

 

 

9.
Non-epithelioid malignant pleural mesothelioma : a total of 1 ( O drug ), no comments

9.
Non - epithelioid malignant pleural mesothelioma

 

Second-line and later indications

Second-line and later indications Second-line and later indications

 

I won't do a detailed review, but I will say it individually:

I won't do a detailed review, but I will say it individually:

 

 

1.
Non-small cell lung cancer, liver cancer, esophageal cancer,Gastric cancer : The first line of major cancers is about to rot.
Don't run the back line any more, hurry up and run forward, what kind of auxiliary new auxiliary
.

1.
Non-small cell lung cancer, liver cancer, esophageal cancer,Gastric cancer 1, non-small cell lung cancer, liver cancer, esophageal cancer,stomach cancerGastric cancer : The first line of major cancers is about to rot.
Don't run the back line any more, hurry up and run forward, what kind of auxiliary new auxiliary
.

 

 

2.
Nasopharyngeal cancer : It is no surprise that three domestic PD-1s occupy this field.
The cancer is not big, so don’t get together.
It’s good for these three to play the Three Kingdoms
.

2.
Nasopharyngeal cancer 2.
Nasopharyngeal cancer : It is no surprise that three domestic PD-1s occupy this field
.

 

  

3.
Hodgkin's lymphoma : 5 models have been approved, and there is one more for playing table mahjong.
There are 13 kinds of PDX in China.
It is estimated that this small cancer cannot be approved for marketing in the future
.

3.
Hodgkin's lymphoma 3.
Hodgkin 's lymphoma : 5 models have been approved, and there is one more than one for playing table mahjong.
There are 13 kinds of PDX in China.
It is estimated that this small cancer cannot be approved for marketing in the future
.

 

 

4.
Melanoma : one domestically imported one, and the second-tier one has been approved for almost four years.
The two big guys hurried to the first-tier, as there are few people who need medicine
.

4.
Melanoma 4.
Melanoma : one domestically imported one, and the second-tier one has been approved for almost four years.
The two bosses hurried to the first-tier, as there are few people in need of medicine
.

 

 

5.
Urothelial cancer : Chinese people seem to be not interested in urinary tract tumors, so they have drawn a border between the two domestic PD1s.
At present, it depends on who is the first to enter Xianyang
.

5.
Urothelial cancer 5.
Urothelial cancer : Chinese people seem not to be interested in urinary tract tumors, so they have drawn a Chu-Han boundary on the two domestic PD1s.
At present, it depends on who is the first to enter Xianyang
.

 

 

6.
MSI-H/dMMR solid tumor : There are 3 models in total, which are also a green channel for shortcuts.
Currently, they can still fight against landlords, and there are three missing ones.
Do not market them with this indication in the future
.

6.
MSI-H/dMMR solid tumors 6.
MSI-H/dMMR solid tumors : There are 3 models in total, which are also a green channel for shortcuts.

.
_

 

 

New indications in 2022

New indications in 2022 New indications in 2022

 

It has been almost 5 months since 22 years, and only one product of slulimumab has been approved, and 5 indications have been approved
.

It has been almost 5 months since 22 years, and one product of slulimumab , slulimumab , has been approved, and five indications have been approved, one product has been approved, and five indications have been approved .

It seems that after the involution highlight of PDX in 2021, the speed of listing is also weak.
As far as application indications are concerned, the second half of the year will be the arrival of another climax, all of which are big indications
.

It seems that after the involution highlight of PDX in 2021, the speed of listing is also weak.
As far as application indications are concerned, the second half of the year will be the arrival of another climax, all of which are big indications
.

 

 

1.
Slulimumab : MSI-H/dMMR solid tumor indication in March 2022

1.
Slulimumab 1.
Slulimumab : Indications for MSI-H/dMMR solid tumors in March 2022

 

 

2.
Three second-line indications for tislelizumab:

2.
Tislelizumab 2, Tislelizumab 3 second-line indications:

 

 

• January 2022 Second-line NSCLC

• March 2022 MSI-H/dMMR solid tumor 2nd line

• April 2022 Second-line esophageal squamous cell carcinoma

January 2022 Second-line NSCLC

January 2022 Second-line NSCLC

January 2022 Second-line NSCLC

March 2022 MSI-H/dMMR solid tumor 2nd line

March 2022 MSI-H/dMMR solid tumor 2nd line

March 2022 MSI-H/dMMR solid tumor 2nd line

April 2022 Second-line esophageal squamous cell carcinoma

April 2022 Second-line esophageal squamous cell carcinoma

April 2022 Second-line esophageal squamous cell carcinoma

 

 

3.
T drugs : Indications for adjuvant treatment of NSCLC in March 2022 (high light)

3.
T drug 3.
T drug : Indications for adjuvant treatment of NSCLC in March 2022 (high light)

 

 

PS: The full picture of the original high-definition version, please reply to "0428" in the background on the official account of the new frontier of tumor
.

PS: The full picture of the original high-definition version, please reply to "0428" in the background on the official account of the new frontier of tumor
.


leave a message here